Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pre-Extraction Phase Clear all
Active, not recruiting Not applicable Interventional

3 Tesla MRI in Patients With Bladder Cancer

NCT00938145
View directory record Official record
Conditions
Bladder Cancer
Interventions
Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy
Procedure · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

NCT07428993
View directory record Official record
Conditions
Pediatric Osteosarcoma
Interventions
Cyclophosphamide, Fludarabine, Mesna, Apheresis, SJCARB7H3_41BBL infusion
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed No phase listed Observational

Studying Biomarkers in Patients With Pancreatic Cancer

NCT00900003
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
protein analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 28, 2026, 5:06 AM EDT
Terminated Phase 1 Interventional Results available

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

NCT02188719
View directory record Official record
Conditions
Liver Transplantation
Interventions
Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373
View directory record Official record
Conditions
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

NCT06444269
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiomics on MRI, microbubble CEUS Contrast Enhanced Ultrasound (CEUS)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

NCT03587844
View directory record Official record
Conditions
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
Interventions
brentuximab vedotin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

NCT03502434
View directory record Official record
Conditions
Tendinopathy
Interventions
SM04755, Vehicle, White Petrolatum, Sodium lauryl sulfate
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional

Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

NCT01227642
View directory record Official record
Conditions
Clinical Stage T2b or Less of Prostate Cancer, Prostate Brachytherapy, Transrectal Prostate Ultrasound Treatment Planning
Interventions
An ultrasound-based technique to identify prostate cancer, pre-implant transrectal ultrasound images and planning, ultrasound-based cancer-specific images
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 28, 2026, 5:06 AM EDT
Enrolling by invitation Phase 1 Interventional

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

NCT04399876
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

NCT03069326
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib, Thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Withdrawn Phase 2 Interventional

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

NCT01445691
View directory record Official record
Conditions
Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
Interventions
5-ALA (Gliolan)
Drug
Lead sponsor
Constantinos Hadjipanayis
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients

NCT00562003
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Tenckhoff Catheter placement, Ad5-delta24RGD
Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

NCT06835387
View directory record Official record
Conditions
Small Bowel Adenocarcinoma
Interventions
Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil, Leucovorin
Drug
Lead sponsor
Tiago Biachi de Castria
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Tampa, Florida • Chicago, Illinois • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Liver Transplantation With Tregs at UCSF

NCT03654040
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Not applicable Interventional

CARE (Chemotherapy Alopecia REduction)

NCT07201389
View directory record Official record
Conditions
Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Chemotherapy Induced Alopecia
Interventions
Scalp Cooling by DigniCap
Device
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Prognosticating Outcomes and Nudging Decisions With Electronic Records in the ICU Trial

NCT03139838
View directory record Official record
Conditions
Critical Illness
Interventions
EHR-Based Intervention A, EHR-Based Intervention B
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Albemarle, North Carolina • Charlotte, North Carolina • Lincolnton, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00621686
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, sorafenib tosylate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
204
States / cities
Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 28, 2026, 5:06 AM EDT
Withdrawn Phase 1 Interventional

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT05950113
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Cervical Mucus Secretion

NCT02969590
View directory record Official record
Conditions
Fertility, Contraception
Interventions
Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional

African American Cancer Clinical Trial Decisions: Testing Tailored Messages

NCT02356549
View directory record Official record
Conditions
Myeloma, Lymphoma, Leukemia
Interventions
EMR Tailoring, Survey Tailoring, Physician Involvement
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 1 Interventional

Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

NCT07676877
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Positron Emission Tomography, Tisagenlecleucel, Total-Body Irradiation
Procedure · Drug · Biological + 1 more
Lead sponsor
Nathan Denlinger
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 5:06 AM EDT